Inflammatory Biomarker Levels over 48 Weeks with Dual Vs Triple Lopinavir/ritonavir-based Therapy: Substudy of a Randomized Trial

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2019 Sep 7

PMID 31490959

Citations 4

Authors

Darrell H S Tan

Maria Jose Rolon

Maria Ines Figueroa

Omar Sued

Ana Gun

Rupert Kaul

Janet M Raboud

Leah Szadkowski

Mark W Hull

Sharon L Walmsley

Pedro Cahn

Affiliations

Soon will be listed here.

Abstract

Background: Inflammation has been associated with increased morbidity and mortality in HIV-positive patients. We compared inflammatory biomarkers with dual therapy using lopinavir/ritonavir plus lamivudine (LPV/r+3TC) versus triple therapy using LPV/r plus two nucleoside reverse transcriptase inhibitors (LPV/r+2NRTIs) in treatment-naïve HIV-positive adults.

Methods: This was a substudy among Argentinian participants in the randomized trial GARDEL. We measured hsCRP, IL-6, MCP-1, TNF, D-dimer and sCD14 from plasma collected at baseline, week 24 and week 48. Generalized estimating equations with an identity/logit link were used to model the average impact of dual versus triple therapy on each biomarker over time, controlling for baseline levels. Additional models estimated the average effect of virologic suppression on biomarker levels over time, adjusting for age, sex, and baseline CD4 count.

Results: Of 191 trial participants enrolled in Argentina, 172 had baseline and follow-up measurements and were included. Median (IQR) age was 35.5 (28.5, 45) years and CD4 cell count was 310 (219, 414) cells/mm3. Dual therapy was not associated with significantly different biomarker levels over 48 weeks relative to triple therapy. Virologic suppression was associated with statistically significant decreases in MCP-1, TNF and D-dimer levels and an unexpected increase in sCD14 levels. No change was observed in hsCRP or the proportion of participants with undetectable IL-6 levels.

Conclusions: In addition to having virologic non-inferiority, LPV/r+3TC dual therapy is generally associated with similar inflammatory biomarker levels over 48 weeks compared to LPV/r+2NRTIs triple therapy in treatment-naïve adults. Further study of dual treatment regimens is warranted.

Citing Articles

HIV-1 Disease Progression and Drug Resistance Mutations among Children on First-Line Antiretroviral Therapy in Ethiopia.

Getaneh Y, Getnet F, Ning F, Rashid A, Liao L, Yi F Biomedicines. 2023; 11(8).

PMID: 37626789 PMC: 10452141. DOI: 10.3390/biomedicines11082293.

Burden of hepatitis B virus and syphilis co-infections and its impact on HIV treatment outcome in Ethiopia: nationwide community-based study.

Getaneh Y, Getnet F, Amogne M, Liao L, Yi F, Shao Y Ann Med. 2023; 55(2):2239828.

PMID: 37498806 PMC: 10375928. DOI: 10.1080/07853890.2023.2239828.

HAART induced inflammation, toxicity and its determinants among HIV positive children in Addis Ababa, Ethiopia.

Getaneh Y, Lejissa T, Getahun T, Khairunisa S, Husada D, Kuntaman K Heliyon. 2023; 9(5):e15779.

PMID: 37215860 PMC: 10195915. DOI: 10.1016/j.heliyon.2023.e15779.

Two-drug regimens for HIV treatment.

Gibas K, Kelly S, Arribas J, Cahn P, Orkin C, Daar E Lancet HIV. 2022; 9(12):e868-e883.

PMID: 36309038 PMC: 10015554. DOI: 10.1016/S2352-3018(22)00249-1.

References

Ridker P, Hennekens C, Buring J, Rifai N . C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342(12):836-43. DOI: 10.1056/NEJM200003233421202. View

Sevigny J, Albert S, McDermott M, McArthur J, Sacktor N, Conant K . Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology. 2004; 63(11):2084-90. DOI: 10.1212/01.wnl.0000145763.68284.15. View

Pai J, Pischon T, Ma J, Manson J, Hankinson S, Joshipura K . Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004; 351(25):2599-610. DOI: 10.1056/NEJMoa040967. View

Kitchens R, Thompson P . Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res. 2005; 11(4):225-9. DOI: 10.1179/096805105X46565. View

Lau B, Sharrett A, Kingsley L, Post W, Palella F, Visscher B . C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med. 2006; 166(1):64-70. DOI: 10.1001/archinte.166.1.64. View

Kuller L, Tracy R, Belloso W, De Wit S, Drummond F, Lane H . Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008; 5(10):e203. PMC: 2570418. DOI: 10.1371/journal.pmed.0050203. View

Smith K, Patel P, Fine D, Bellos N, Sloan L, Lackey P . Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009; 23(12):1547-56. DOI: 10.1097/QAD.0b013e32832cbcc2. View

Tien P, Choi A, Zolopa A, Benson C, Tracy R, Scherzer R . Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr. 2010; 55(3):316-22. PMC: 2955817. DOI: 10.1097/QAI.0b013e3181e66216. View

Sandler N, Wand H, Roque A, Law M, Nason M, Nixon D . Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011; 203(6):780-90. PMC: 3071127. DOI: 10.1093/infdis/jiq118. View

10.

Boulware D, Hullsiek K, Puronen C, Rupert A, Baker J, French M . Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis. 2011; 203(11):1637-46. PMC: 3096784. DOI: 10.1093/infdis/jir134. View

11.

Justice A, Freiberg M, Tracy R, Kuller L, Tate J, Goetz M . Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV?. Clin Infect Dis. 2012; 54(7):984-94. PMC: 3297653. DOI: 10.1093/cid/cir989. View

12.

Ledwaba L, Tavel J, Khabo P, Maja P, Qin J, Sangweni P . Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease. PLoS One. 2012; 7(3):e24243. PMC: 3308955. DOI: 10.1371/journal.pone.0024243. View

13.

Ananworanich J, Schuetz A, Vandergeeten C, Sereti I, de Souza M, Rerknimitr R . Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One. 2012; 7(3):e33948. PMC: 3316511. DOI: 10.1371/journal.pone.0033948. View

14.

McComsey G, Kitch D, Daar E, Tierney C, Jahed N, Melbourne K . Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS. 2012; 26(11):1371-85. PMC: 3560932. DOI: 10.1097/QAD.0b013e328354f4fb. View

15.

Marchetti G, Merlini E, Sinigaglia E, Iannotti N, Bai F, Savoldi A . Immune reconstitution in HIV+ subjects on lopinavir/ritonavir-based HAART according to the severity of pre-therapy CD4+. Curr HIV Res. 2012; 10(7):597-605. DOI: 10.2174/157016212803306032. View

16.

Gupta S, Shen C, Moe S, Kamendulis L, Goldman M, Dube M . Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study. PLoS One. 2012; 7(9):e45716. PMC: 3447812. DOI: 10.1371/journal.pone.0045716. View

17.

Vesterbacka J, Nowak P, Barqasho B, Abdurahman S, Nystrom J, Nilsson S . Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy. PLoS One. 2013; 8(1):e55038. PMC: 3557242. DOI: 10.1371/journal.pone.0055038. View

18.

Taiwo B, Matining R, Zheng L, Lederman M, Rinaldo C, Kim P . Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy. J Antimicrob Chemother. 2013; 68(8):1857-61. PMC: 3716396. DOI: 10.1093/jac/dkt120. View

19.

Kumar A, Abbas W, Herbein G . TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy?. Mediators Inflamm. 2014; 2013:484378. PMC: 3880767. DOI: 10.1155/2013/484378. View

20.

Hattab S, Guihot A, Guiguet M, Fourati S, Carcelain G, Caby F . Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study. BMC Infect Dis. 2014; 14:122. PMC: 3945800. DOI: 10.1186/1471-2334-14-122. View